11:56 AM EST - Aurinia Pharmaceuticals Inc. : Announced the enrollment of the first patients into the AURORA 2 extension study in lupus nephritis and the initiation of its Phase II trial in focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc.
shares T.AUP are trading unchanged at $7.60.
